Search
Fortress Biotech Inc
FBIOAdd to Watchlist
3.040USD
-0.050-1.62%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
100.89MMarket Cap
0.79P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.62%
5 Days
+0.66%
1 Month
+14.72%
6 Months
-24.57%
Year to Date
-16.94%
1 Year
+66.12%
Key Figures
3.090Open
3.195High
331.90KVolume
0.79P/E TTM
4.77P/E Dynamic
--Dividend TTM
1.00%Turnover Ratio
3.090Prev. Close
3.000Low
697.96KTurnover
LossP/E Static
0.62P/B
0.00%Div Yield TTM
48.21%ROA
4.53052wk High
1.04Volume Ratio
-55.89MNet Profit
33.19MShares
3.8490EPS TTM
1.22Beta
129.25%ROE
1.70052wk Low
6.31%Amplitude
54.21%Gross Margin
100.89MMarket Cap
4.45Reward/Risk
4.13%Risk Rate
TradingKey Stock Score of Fortress Biotech Inc
Currency: USD Updated: 2026-07-01Key Insights
Fortress Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Fortress Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Fortress Biotech Inc Highlights
StrengthsRisks
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Growing
The company is in a growing phase, with the latest annual income totaling USD 63.26M.
Overvalued
The company’s latest PE is 0.80, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.02M shares, decreasing 12.64% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
+272.88%
Upside Space
Fortress Biotech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Fortress Biotech Inc Info
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Ticker SymbolFBIO
CompanyFortress Biotech Inc
CEORosenwald (Lindsay A)
Websitehttps://www.fortressbiotech.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53072.200
+229.700 (+0.43%)
29426.700
+115.300 (+0.39%)
7499.100
+27.600 (+0.37%)
14817.000
+14.000 (+0.10%)
68996.000
+848.000 (+1.24%)
6372.400
+19.600 (+0.31%)
68.403
+0.059 (+0.09%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4186.930
+65.020 (+1.58%)
FAQs
What is the current price of Fortress Biotech Inc (FBIO)?
The current price of Fortress Biotech Inc (FBIO) is 3.04.
What is the symbol of Fortress Biotech Inc?
The ticker symbol of Fortress Biotech Inc is FBIO.
What is the 52-week high of Fortress Biotech Inc?
The 52-week high of Fortress Biotech Inc is 4.53.
What is the 52-week low of Fortress Biotech Inc?
The 52-week low of Fortress Biotech Inc is 1.70.
What is the market capitalization of Fortress Biotech Inc?
The market capitalization of Fortress Biotech Inc is 100.89M.
Is Fortress Biotech Inc (FBIO) currently rated as Buy, Hold, or Sell?
According to analysts, Fortress Biotech Inc (FBIO) has an overall rating of Buy, with a price target of 11.00.
What is the Earnings Per Share (EPS TTM) of Fortress Biotech Inc (FBIO)?
The Earnings Per Share (EPS TTM) of Fortress Biotech Inc (FBIO) is -0.07.